158 related articles for article (PubMed ID: 14695140)
1. Aberrant promoter methylation of laminin-5-encoding genes in prostate cancers and its relationship to clinicopathological features.
Sathyanarayana UG; Padar A; Suzuki M; Maruyama R; Shigematsu H; Hsieh JT; Frenkel EP; Gazdar AF
Clin Cancer Res; 2003 Dec; 9(17):6395-400. PubMed ID: 14695140
[TBL] [Abstract][Full Text] [Related]
2. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma.
Sathyanarayana UG; Padar A; Huang CX; Suzuki M; Shigematsu H; Bekele BN; Gazdar AF
Clin Cancer Res; 2003 Dec; 9(17):6389-94. PubMed ID: 14695139
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation.
Padar A; Sathyanarayana UG; Suzuki M; Maruyama R; Hsieh JT; Frenkel EP; Minna JD; Gazdar AF
Clin Cancer Res; 2003 Oct; 9(13):4730-4. PubMed ID: 14581343
[TBL] [Abstract][Full Text] [Related]
4. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features.
Maruyama R; Toyooka S; Toyooka KO; Virmani AK; Zöchbauer-Müller S; Farinas AJ; Minna JD; McConnell J; Frenkel EP; Gazdar AF
Clin Cancer Res; 2002 Feb; 8(2):514-9. PubMed ID: 11839671
[TBL] [Abstract][Full Text] [Related]
5. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia.
Kang GH; Lee S; Lee HJ; Hwang KS
J Pathol; 2004 Feb; 202(2):233-40. PubMed ID: 14743506
[TBL] [Abstract][Full Text] [Related]
6. Co-expression of laminin β3 and γ2 chains and epigenetic inactivation of laminin α3 chain in gastric cancer.
Ii M; Yamamoto H; Taniguchi H; Adachi Y; Nakazawa M; Ohashi H; Tanuma T; Sukawa Y; Suzuki H; Sasaki S; Imai K; Shinomura Y
Int J Oncol; 2011 Sep; 39(3):593-9. PubMed ID: 21617852
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic inactivation of laminin-5-encoding genes in lung cancers.
Sathyanarayana UG; Toyooka S; Padar A; Takahashi T; Brambilla E; Minna JD; Gazdar AF
Clin Cancer Res; 2003 Jul; 9(7):2665-72. PubMed ID: 12855645
[TBL] [Abstract][Full Text] [Related]
8. Multigene methylation analysis for detection and staging of prostate cancer.
Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
[TBL] [Abstract][Full Text] [Related]
9. Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease.
Singal R; Ferdinand L; Reis IM; Schlesselman JJ
Oncol Rep; 2004 Sep; 12(3):631-7. PubMed ID: 15289848
[TBL] [Abstract][Full Text] [Related]
10. Aberrant up-regulation of LAMB3 and LAMC2 by promoter demethylation in gastric cancer.
Kwon OH; Park JL; Kim M; Kim JH; Lee HC; Kim HJ; Noh SM; Song KS; Yoo HS; Paik SG; Kim SY; Kim YS
Biochem Biophys Res Commun; 2011 Mar; 406(4):539-45. PubMed ID: 21345334
[TBL] [Abstract][Full Text] [Related]
11. MT1G hypermethylation is associated with higher tumor stage in prostate cancer.
Henrique R; Jerónimo C; Hoque MO; Nomoto S; Carvalho AL; Costa VL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1274-8. PubMed ID: 15894685
[TBL] [Abstract][Full Text] [Related]
12. Methylation of the ASC gene promoter is associated with aggressive prostate cancer.
Collard RL; Harya NS; Monzon FA; Maier CE; O'Keefe DS
Prostate; 2006 May; 66(7):687-95. PubMed ID: 16425203
[TBL] [Abstract][Full Text] [Related]
13. HRK inactivation associated with promoter methylation and LOH in prostate cancer.
Higuchi T; Nakamura M; Shimada K; Ishida E; Hirao K; Konishi N
Prostate; 2008 Jan; 68(1):105-13. PubMed ID: 18008329
[TBL] [Abstract][Full Text] [Related]
14. Promoter CpG methylation of tumor suppressor genes in colorectal cancer and its relationship to clinical features.
Lin SY; Yeh KT; Chen WT; Chen HC; Chen ST; Chiou HY; Chang JG
Oncol Rep; 2004 Feb; 11(2):341-8. PubMed ID: 14719065
[TBL] [Abstract][Full Text] [Related]
15. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects.
Hoque MO; Topaloglu O; Begum S; Henrique R; Rosenbaum E; Van Criekinge W; Westra WH; Sidransky D
J Clin Oncol; 2005 Sep; 23(27):6569-75. PubMed ID: 16170165
[TBL] [Abstract][Full Text] [Related]
16. Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features.
Kim DS; Kim MJ; Lee JY; Kim YZ; Kim EJ; Park JY
Cancer; 2007 Dec; 110(12):2785-92. PubMed ID: 17960794
[TBL] [Abstract][Full Text] [Related]
17. Hypermethylation of the GATA genes in lung cancer.
Guo M; Akiyama Y; House MG; Hooker CM; Heath E; Gabrielson E; Yang SC; Han Y; Baylin SB; Herman JG; Brock MV
Clin Cancer Res; 2004 Dec; 10(23):7917-24. PubMed ID: 15585625
[TBL] [Abstract][Full Text] [Related]
18. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients.
Henrique R; Ribeiro FR; Fonseca D; Hoque MO; Carvalho AL; Costa VL; Pinto M; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
Clin Cancer Res; 2007 Oct; 13(20):6122-9. PubMed ID: 17947477
[TBL] [Abstract][Full Text] [Related]
19. Molecular detection of noninvasive and invasive bladder tumor tissues and exfoliated cells by aberrant promoter methylation of laminin-5 encoding genes.
Sathyanarayana UG; Maruyama R; Padar A; Suzuki M; Bondaruk J; Sagalowsky A; Minna JD; Frenkel EP; Grossman HB; Czerniak B; Gazdar AF
Cancer Res; 2004 Feb; 64(4):1425-30. PubMed ID: 14973053
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci.
Bastian PJ; Ellinger J; Wellmann A; Wernert N; Heukamp LC; Müller SC; von Ruecker A
Clin Cancer Res; 2005 Jun; 11(11):4097-106. PubMed ID: 15930345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
